Survival following primary androgen deprivation therapy for localized intermediate- Or high-risk prostate cancer: Comparison with the life expectancy of the age-matched normal population

Kazuhiro Matsumoto, Masayuki Hagiwara, Nobuyuki Tanaka, Nozomi Hayakawa, Masaru Ishida, Akiharu Ninomiya, Yosuke Nakajima, So Nakamura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The representative guidelines do not recommend androgen deprivation therapy (ADT) as a primary treatment for localized prostate cancer. However, in clinical practice, the use of primary ADT for localized prostate cancer has been widespread, especially among older patients. We performed a retrospective review of the efficacy of primary ADT for localized prostate cancer and compared their outcomes with the life expectancy of the normal population. The study cohort consisted of 410 men diagnosed with localized intermediate- or high-risk prostate cancer over the period 1992-2012 at five institutions. All patients underwent ADT as a primary cancer therapy, and mean follow-up was 6.0 years. Their progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) rates were calculated. Patients' expected survival rates were estimated by the Hakulinen method. Multivariate analysis demonstrated that Gleason score ≥8 and cT3a were independent risk factors for all of PFS, CSS, and OS. In patients who have none or one of these risk factors, minimum OS rates were not inferior to the expected survival curves of the normal population. Meanwhile, in patients with both risk factors, the OS curve fell below the expected survival rates, especially after 6 years of follow-up. We conclude that primary ADT might be one of the therapeutic options for localized intermediate- and high-risk prostate cancer. However, for high-risk cases with Gleason score ≥8 and cT3a, the choice of primary ADT should be deliberated carefully because the OS of these cases was inferior to the expected survival, especially at a late time point.

Original languageEnglish
Article number979
JournalMedical Oncology
Volume31
Issue number6
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Life Expectancy
Androgens
Prostatic Neoplasms
Survival
Population
Survival Rate
Therapeutics
Neoplasm Grading
Disease-Free Survival
Neoplasms
Cohort Studies
Multivariate Analysis
Guidelines

Keywords

  • Androgen deprivation
  • High-risk
  • Hormonal therapy
  • Intermediate-risk
  • Localized
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Medicine(all)

Cite this

Survival following primary androgen deprivation therapy for localized intermediate- Or high-risk prostate cancer : Comparison with the life expectancy of the age-matched normal population. / Matsumoto, Kazuhiro; Hagiwara, Masayuki; Tanaka, Nobuyuki; Hayakawa, Nozomi; Ishida, Masaru; Ninomiya, Akiharu; Nakajima, Yosuke; Nakamura, So.

In: Medical Oncology, Vol. 31, No. 6, 979, 2014.

Research output: Contribution to journalArticle

@article{6f8d9982ac634ca2bbc3b138827eb231,
title = "Survival following primary androgen deprivation therapy for localized intermediate- Or high-risk prostate cancer: Comparison with the life expectancy of the age-matched normal population",
abstract = "The representative guidelines do not recommend androgen deprivation therapy (ADT) as a primary treatment for localized prostate cancer. However, in clinical practice, the use of primary ADT for localized prostate cancer has been widespread, especially among older patients. We performed a retrospective review of the efficacy of primary ADT for localized prostate cancer and compared their outcomes with the life expectancy of the normal population. The study cohort consisted of 410 men diagnosed with localized intermediate- or high-risk prostate cancer over the period 1992-2012 at five institutions. All patients underwent ADT as a primary cancer therapy, and mean follow-up was 6.0 years. Their progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) rates were calculated. Patients' expected survival rates were estimated by the Hakulinen method. Multivariate analysis demonstrated that Gleason score ≥8 and cT3a were independent risk factors for all of PFS, CSS, and OS. In patients who have none or one of these risk factors, minimum OS rates were not inferior to the expected survival curves of the normal population. Meanwhile, in patients with both risk factors, the OS curve fell below the expected survival rates, especially after 6 years of follow-up. We conclude that primary ADT might be one of the therapeutic options for localized intermediate- and high-risk prostate cancer. However, for high-risk cases with Gleason score ≥8 and cT3a, the choice of primary ADT should be deliberated carefully because the OS of these cases was inferior to the expected survival, especially at a late time point.",
keywords = "Androgen deprivation, High-risk, Hormonal therapy, Intermediate-risk, Localized, Prostate cancer",
author = "Kazuhiro Matsumoto and Masayuki Hagiwara and Nobuyuki Tanaka and Nozomi Hayakawa and Masaru Ishida and Akiharu Ninomiya and Yosuke Nakajima and So Nakamura",
year = "2014",
doi = "10.1007/s12032-014-0979-3",
language = "English",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "6",

}

TY - JOUR

T1 - Survival following primary androgen deprivation therapy for localized intermediate- Or high-risk prostate cancer

T2 - Comparison with the life expectancy of the age-matched normal population

AU - Matsumoto, Kazuhiro

AU - Hagiwara, Masayuki

AU - Tanaka, Nobuyuki

AU - Hayakawa, Nozomi

AU - Ishida, Masaru

AU - Ninomiya, Akiharu

AU - Nakajima, Yosuke

AU - Nakamura, So

PY - 2014

Y1 - 2014

N2 - The representative guidelines do not recommend androgen deprivation therapy (ADT) as a primary treatment for localized prostate cancer. However, in clinical practice, the use of primary ADT for localized prostate cancer has been widespread, especially among older patients. We performed a retrospective review of the efficacy of primary ADT for localized prostate cancer and compared their outcomes with the life expectancy of the normal population. The study cohort consisted of 410 men diagnosed with localized intermediate- or high-risk prostate cancer over the period 1992-2012 at five institutions. All patients underwent ADT as a primary cancer therapy, and mean follow-up was 6.0 years. Their progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) rates were calculated. Patients' expected survival rates were estimated by the Hakulinen method. Multivariate analysis demonstrated that Gleason score ≥8 and cT3a were independent risk factors for all of PFS, CSS, and OS. In patients who have none or one of these risk factors, minimum OS rates were not inferior to the expected survival curves of the normal population. Meanwhile, in patients with both risk factors, the OS curve fell below the expected survival rates, especially after 6 years of follow-up. We conclude that primary ADT might be one of the therapeutic options for localized intermediate- and high-risk prostate cancer. However, for high-risk cases with Gleason score ≥8 and cT3a, the choice of primary ADT should be deliberated carefully because the OS of these cases was inferior to the expected survival, especially at a late time point.

AB - The representative guidelines do not recommend androgen deprivation therapy (ADT) as a primary treatment for localized prostate cancer. However, in clinical practice, the use of primary ADT for localized prostate cancer has been widespread, especially among older patients. We performed a retrospective review of the efficacy of primary ADT for localized prostate cancer and compared their outcomes with the life expectancy of the normal population. The study cohort consisted of 410 men diagnosed with localized intermediate- or high-risk prostate cancer over the period 1992-2012 at five institutions. All patients underwent ADT as a primary cancer therapy, and mean follow-up was 6.0 years. Their progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) rates were calculated. Patients' expected survival rates were estimated by the Hakulinen method. Multivariate analysis demonstrated that Gleason score ≥8 and cT3a were independent risk factors for all of PFS, CSS, and OS. In patients who have none or one of these risk factors, minimum OS rates were not inferior to the expected survival curves of the normal population. Meanwhile, in patients with both risk factors, the OS curve fell below the expected survival rates, especially after 6 years of follow-up. We conclude that primary ADT might be one of the therapeutic options for localized intermediate- and high-risk prostate cancer. However, for high-risk cases with Gleason score ≥8 and cT3a, the choice of primary ADT should be deliberated carefully because the OS of these cases was inferior to the expected survival, especially at a late time point.

KW - Androgen deprivation

KW - High-risk

KW - Hormonal therapy

KW - Intermediate-risk

KW - Localized

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84905436414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905436414&partnerID=8YFLogxK

U2 - 10.1007/s12032-014-0979-3

DO - 10.1007/s12032-014-0979-3

M3 - Article

C2 - 24781338

AN - SCOPUS:84905436414

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 6

M1 - 979

ER -